Safety, Tolerability, and Pharmacokinetics Study of Human Monoclonal Antibody BRII-198
Status:
Completed
Trial end date:
2021-02-03
Target enrollment:
Participant gender:
Summary
This is a phase 1 study in which healthy adult volunteers will receive BRII-198 or placebo
and will be assessed for safety, tolerability, and pharmacokinetics.